Hepatect (Human Hepatitis B Immunoglobulin)

Hepatect is indicated for specific situations where passive immunity against hepatitis B virus is required.

• Post‑exposure prophylaxis for individuals who have been exposed to hepatitis B virus and are not adequately protected by vaccination.
• Prevention of hepatitis B virus recurrence in patients undergoing orthotopic liver transplantation.
• Supplementation of anti‑HBs antibodies in patients with chronic liver disease who have low endogenous antibody levels.
• Use in immunocompromised patients who cannot mount an adequate response to hepatitis B vaccination.
• Administration to newborns of hepatitis B‑positive mothers when active immunization is delayed.

The safety profile of Hepatect reflects the typical reactions observed with human immunoglobulin preparations administered intravenously.

Common

• Mild fever, chills, or rigors that develop within minutes to a few hours after the infusion.
• Headache, dizziness, or a sensation of light‑headedness during or shortly after the injection.
• Nausea, vomiting, abdominal cramping, or loss of appetite occurring in the first 24 hours.
• Localized pain, redness, swelling, or a small bruise at the site where the intravenous line was placed.
• Transient low blood pressure or rapid heart rate observed during the infusion.

Serious

• Severe allergic reactions including anaphylaxis, angioedema, or widespread urticaria requiring emergency treatment.
• Acute hemolytic transfusion reaction manifested by hemoglobinuria, back pain, or sudden drop in hemoglobin levels.
• Renal dysfunction such as acute kidney injury or worsening of pre‑existing renal disease.

When prescribing or administering Hepatect, clinicians should consider several precautionary measures to ensure safe use.

• Assess patient’s history for prior reactions to blood products or immunoglobulin therapy.
• Verify hepatitis B surface antigen and antibody status before use to avoid unnecessary treatment.
• Monitor vital signs and for signs of hypersensitivity during the infusion and for at least 30 minutes afterward.
• Adjust dosage or infusion rate in patients with renal impairment or fluid overload risk.
• Avoid use in individuals with known severe IgA deficiency unless IgA‑deficient preparations are available.
• Consider pregnancy status; the safety profile in pregnant women has not been established.
• Ensure appropriate storage and handling of the product according to manufacturer guidelines.

Hepatect may interact with other medications or clinical conditions; awareness of these interactions helps to minimize adverse outcomes.

Avoid

• Concurrent administration of other human immunoglobulin products, which can increase the risk of hyperviscosity.
• Live viral vaccines given within 4 weeks of Hepatect infusion, as passive antibodies may diminish vaccine efficacy.

Use with caution

• Anticoagulants or antiplatelet agents, because infusion‑related vascular reactions can exacerbate bleeding risk.
• Immunosuppressive agents, which may alter the patient’s response to passive immunization.
• Renal‑clearing drugs (e.g., aminoglycosides, contrast media) in patients with compromised kidney function, due to potential additive nephrotoxicity.